Lymphangioleiomyomatosis (LAM): CT Findings, Recurrent Spontaneous Pneumothorax, and the Role of Sirolimus
How to Recognize Diffuse Pulmonary Cysts, Establish the Diagnosis, and Understand the Clinical Significance of Recurrent Pneumothorax
Executive Answer
Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease that predominantly affects women. Its characteristic imaging appearance consists of multiple, diffuse, thin-walled pulmonary cysts distributed throughout both lungs. Spontaneous pneumothorax may be the first major clinical manifestation and can recur because of progressive cystic destruction of the lung parenchyma.
On chest CT, the combination of diffuse pulmonary cysts and pneumothorax should immediately raise suspicion for LAM. Definitive diagnosis can be established through characteristic histopathology and immunohistochemical findings. Sirolimus, an inhibitor of the mechanistic target of rapamycin (mTOR) pathway, is an important disease-modifying treatment for patients with abnormal or declining lung function.
1. Why This Case Matters
A spontaneous pneumothorax in a relatively young woman may initially appear to be an isolated pulmonary emergency. However, when chest CT reveals diffuse cystic abnormalities in addition to pleural air, the diagnostic question changes substantially.
The radiologist must move beyond identifying the pneumothorax and investigate the underlying pulmonary disease.
This distinction is clinically important because lymphangioleiomyomatosis is not simply a condition associated with occasional lung collapse. It is a multisystem disease characterized by abnormal proliferation of LAM cells, progressive destruction of lung tissue, cyst formation, and potential involvement of extrapulmonary organs.
The presenting case illustrates several important diagnostic and management issues:
Diffuse pulmonary cysts can provide the first major clue to an underlying systemic disease.
Spontaneous pneumothorax may be the initial presentation of LAM.
Recurrent pneumothorax can occur despite previous pleurodesis.
Histopathology and immunohistochemistry can establish the diagnosis.
Pulmonary function testing is essential for assessing disease severity.
mTOR inhibition can improve or stabilize pulmonary function in appropriately selected patients.
For radiologists, the most important lesson is straightforward: A pneumothorax accompanied by diffuse pulmonary cysts should prompt an investigation for an underlying cystic lung disease rather than being interpreted as an isolated event.
2. Clinical Scenario: A 46-Year-Old Woman With Acute Chest Pain
A 46-year-old woman presented to the emergency department with acute chest pain following several months of persistent dyspnea.
Her initial clinical findings included:
Age: 46 years
Sex: Female
Oxygen saturation: 92% while breathing room air
Physical examination: Decreased breath sounds on the right side
Primary symptoms: Chronic dyspnea followed by acute chest pain
Chest CT demonstrated a large right-sided pneumothorax accompanied by diffuse pulmonary parenchymal cysts.
The patient underwent mechanical pleurodesis and surgical wedge biopsy.
Histopathologic examination demonstrated numerous thin-walled cystic structures. Spindle-shaped cells expressing both smooth-muscle and melanocytic markers were identified along the cyst walls, confirming lymphangioleiomyomatosis.
Several weeks after the initial presentation, the patient developed recurrent sharp chest pain and dyspnea. Chest radiography demonstrated a contralateral spontaneous pneumothorax caused by cyst rupture.
Despite pleurodesis, respiratory symptoms persisted. Pulmonary function testing demonstrated a forced expiratory volume in one second (FEV1) of 44% predicted.
Treatment with sirolimus was initiated. Within three months, exercise tolerance improved, and FEV1 increased to 67% predicted. However, fatigue and chest discomfort persisted, preventing the patient from returning to work.
This clinical course illustrates an important distinction between physiological improvement and complete functional recovery. An improvement in pulmonary function does not necessarily translate into immediate restoration of occupational or everyday activities.
3. Understanding Lymphangioleiomyomatosis
3.1 What Is LAM?
Lymphangioleiomyomatosis is a rare multisystem neoplastic disease characterized by the proliferation of abnormal smooth-muscle-like cells, known as LAM cells.
Although the lungs are the principal organs affected, LAM can also involve lymphatic structures, blood vessels, kidneys, and retroperitoneal tissues.
The disease predominantly affects women and may occur in two clinical settings:
Sporadic LAM
This form occurs independently of tuberous sclerosis complex (TSC).
TSC-associated LAM
This form occurs in patients with tuberous sclerosis complex, an inherited disorder associated with abnormalities affecting multiple organ systems.
Both forms share important molecular mechanisms involving dysregulation of the mTOR signaling pathway.
3.2 Molecular Pathogenesis: The TSC1/TSC2–mTOR Pathway
The molecular basis of LAM is closely associated with abnormalities involving the TSC1 and TSC2 genes.
Under normal physiological conditions, the proteins hamartin and tuberin, encoded by TSC1 and TSC2, respectively, form a complex that suppresses excessive mTOR signaling.
The mechanistic target of rapamycin pathway regulates several important cellular processes, including:
Cell growth
Protein synthesis
Cellular proliferation
Metabolic regulation
Cell survival
Loss of normal TSC1/TSC2 tumor-suppressor function results in abnormal activation of mTOR signaling.
This promotes the proliferation and survival of LAM cells, contributing to progressive pulmonary involvement.
Figure concept: Molecular pathway illustrating TSC1/TSC2 dysfunction and mTOR activation in lymphangioleiomyomatosis.
In the lungs, abnormal LAM cell proliferation and associated tissue remodeling contribute to the formation of multiple pulmonary cysts.
The progressive destruction of normal lung architecture eventually impairs pulmonary function.
This molecular mechanism also explains why mTOR inhibitors have become central to the treatment of selected patients with LAM.
4. Chest CT Findings of Lymphangioleiomyomatosis
4.1 The Most Important Imaging Feature: Diffuse Pulmonary Cysts
High-resolution computed tomography (HRCT) is the principal imaging modality for evaluating suspected pulmonary LAM.
The characteristic CT appearance consists of:
Multiple pulmonary cysts.
Thin and relatively regular cyst walls.
Round or nearly round morphology.
Diffuse bilateral distribution.
Variable cyst size.
Relatively preserved intervening lung parenchyma, particularly during earlier disease stages.
The cysts may involve both upper and lower lung zones, including the costophrenic regions.
Unlike certain other cystic lung diseases, LAM typically demonstrates a relatively uniform distribution of cysts throughout the lungs.
This distribution is an important diagnostic clue.
4.2 Interpreting the CT in the Present Case
Figure 1. Coronal chest CT demonstrating a large pneumothorax and diffuse pulmonary cysts.
The major findings are:
A large right-sided pneumothorax.
Multiple diffuse pulmonary cysts.
Extensive cystic involvement of the pulmonary parenchyma.
The coexistence of pneumothorax and diffuse cystic lung disease is particularly important.
A pneumothorax can result from rupture of a subpleural cyst, allowing air to enter the pleural space.
The resulting loss of normal negative intrapleural pressure leads to partial or complete lung collapse.
In a patient with LAM, the presence of multiple cysts provides a structural explanation for the increased susceptibility to spontaneous pneumothorax.
4.3 Why Does LAM Produce Pneumothorax?
LAM progressively alters the structural integrity of the pulmonary parenchyma.
As cysts develop and enlarge, the surrounding alveolar and supporting tissues become increasingly vulnerable.
Cyst rupture can result in:
Leakage of air into the pleural space.
Sudden pleuritic chest pain.
Acute worsening of dyspnea.
Reduced oxygen saturation.
Partial or complete lung collapse.
Importantly, recurrent pneumothorax is a recognized clinical complication of LAM.
Therefore, identifying the underlying cystic lung disease during the initial imaging examination has important implications for subsequent management.
4.4 Additional Imaging Findings to Investigate
Although pulmonary cysts are the dominant imaging manifestation, LAM can involve multiple extrapulmonary structures.
A comprehensive imaging evaluation should consider:
Renal angiomyolipomas
Renal angiomyolipomas are important extrapulmonary manifestations. These lesions contain varying proportions of blood vessels, smooth muscle, and adipose tissue.
On CT, macroscopic fat within a renal lesion is a particularly useful diagnostic feature.
Lymphangioleiomyomas
These lesions may develop in the retroperitoneum, pelvis, or mediastinum and can appear as cystic or multiloculated masses.
Lymphatic abnormalities
Chylous pleural effusion and chylous ascites may occur because of lymphatic involvement.
Other manifestations
Additional findings may include enlarged lymph nodes and other manifestations associated with TSC.
The absence of extrapulmonary abnormalities does not exclude sporadic LAM.
5. Histopathology and Immunohistochemistry
Imaging findings are essential for recognizing LAM, but tissue examination can provide definitive confirmation when required.
Figure 2. Histopathologic appearance of lymphangioleiomyomatosis demonstrating abnormal spindle-shaped cells associated with cystic pulmonary architecture.
The biopsy specimen in this case demonstrated numerous thin-walled cysts.
Spindle-shaped cells expressing smooth-muscle and melanocytic markers were identified along the cyst walls.
This combination is characteristic of LAM.
5.1 Immunohistochemical Markers
LAM cells demonstrate a distinctive immunohistochemical profile.
Commonly used markers include:
Marker | Diagnostic significance |
|---|---|
Smooth muscle actin (SMA) | Supports smooth-muscle differentiation |
Desmin | Supports smooth-muscle differentiation |
HMB-45 | Melanocytic marker frequently expressed by LAM cells |
Melan-A | Additional melanocytic marker |
D2-40 | May demonstrate lymphatic endothelial differentiation in relevant tissue components |
The co-expression of smooth-muscle and melanocytic markers is particularly useful when distinguishing LAM from other pulmonary spindle-cell proliferations.
The HMB-45-positive cell population is an important pathological clue.
5.2 Why Is Immunohistochemistry Important?
The pathological differential diagnosis of cystic lung disease includes several conditions that can produce structural abnormalities but have different cellular characteristics.
Immunohistochemistry helps establish the nature of the proliferating cells and strengthens diagnostic confidence.
However, biopsy is not necessary in every patient.
When characteristic HRCT findings are accompanied by established confirmatory features, a clinical diagnosis may be possible without surgical lung biopsy.
Serum vascular endothelial growth factor-D (VEGF-D) testing is also an important noninvasive diagnostic tool.
In patients with characteristic cystic CT findings but no additional confirmatory features, the ATS/JRS guidelines recommend VEGF-D testing before proceeding to diagnostic lung biopsy. A serum VEGF-D level of at least 800 pg/mL can support a definite diagnosis in the appropriate clinical context (1, 2).
6. Differential Diagnosis of Diffuse Pulmonary Cystic Disease
One of the most important responsibilities of a radiologist is distinguishing LAM from other diseases associated with diffuse pulmonary cysts.
The differential diagnosis should be based on:
Patient age and sex.
Clinical history.
Cyst morphology.
Distribution of cysts.
Associated pulmonary abnormalities.
Extrapulmonary manifestations.
Laboratory and pathological findings when available.
6.1 Pulmonary Langerhans Cell Histiocytosis
Pulmonary Langerhans cell histiocytosis (PLCH) is strongly associated with cigarette smoking.
Typical CT findings include:
Multiple pulmonary nodules.
Cavitating nodules.
Irregular or bizarre-shaped cysts.
Predominant upper- and middle-lung involvement.
Relative sparing of the costophrenic angles.
These findings differ from the more uniform, diffuse, round, thin-walled cysts typically observed in LAM.
6.2 Birt-Hogg-Dubé Syndrome
Birt-Hogg-Dubé syndrome is an inherited disorder associated with FLCN gene abnormalities.
Pulmonary manifestations include multiple cysts and an increased risk of spontaneous pneumothorax.
Characteristic CT findings include:
Irregularly shaped cysts.
Variable cyst size.
Predominant lower-lung and medial distribution.
Subpleural and perivascular cysts.
Associated clinical findings may include fibrofolliculomas and renal tumors.
6.3 Lymphocytic Interstitial Pneumonia
Lymphocytic interstitial pneumonia (LIP) may be associated with autoimmune diseases, particularly Sjögren syndrome.
CT findings can include:
Thin-walled pulmonary cysts.
Ground-glass opacities.
Centrilobular nodules.
Interlobular septal thickening.
Peribronchovascular abnormalities.
The presence of additional interstitial abnormalities helps distinguish LIP from uncomplicated LAM.
6.4 Emphysema
Pulmonary emphysema can resemble cystic lung disease, particularly when the distinction between enlarged airspaces and true cysts is not carefully evaluated.
Emphysema is characterized by permanent enlargement of airspaces distal to the terminal bronchioles, accompanied by destruction of alveolar walls.
Unlike typical LAM cysts, emphysematous spaces generally lack clearly defined walls.
Centrilobular and paraseptal emphysema also demonstrate characteristic distributions.
6.5 Pneumocystis jirovecii Pneumonia
Pneumocystis jirovecii pneumonia (PJP) may occasionally produce pulmonary cysts, particularly in immunocompromised patients.
However, the typical presentation is dominated by bilateral ground-glass opacities, hypoxemia, and respiratory symptoms.
Pneumothorax may occur as a complication, but the overall clinical and imaging pattern differs from typical LAM.
6.6 Comparative Imaging Features
Disease | Typical CT appearance | Important distinguishing feature |
|---|---|---|
LAM | Diffuse, round, thin-walled cysts | Relatively uniform bilateral distribution |
PLCH | Nodules and irregular cysts | Upper-lung predominance and costophrenic sparing |
Birt-Hogg-Dubé syndrome | Variable irregular cysts | Lower-medial and subpleural distribution |
LIP | Cysts with ground-glass opacities and nodules | Associated interstitial abnormalities |
Emphysema | Low-attenuation areas without distinct walls | Destruction of alveolar architecture |
PJP | Ground-glass opacities, sometimes with cysts | Immunocompromised clinical context |
Radiology pearl: The shape and distribution of pulmonary cysts are often more diagnostically useful than the number of cysts alone.
7. Diagnostic Approach to Suspected LAM
A systematic diagnostic approach can reduce unnecessary invasive procedures and improve recognition of associated disease.
Step 1: Identify the Clinical Presentation
Consider LAM in women presenting with:
Spontaneous pneumothorax.
Progressive dyspnea.
Recurrent pleuritic chest pain.
Chylous pleural effusion.
Unexplained obstructive pulmonary physiology.
Step 2: Evaluate HRCT Findings
Assess:
Number and distribution of pulmonary cysts.
Cyst wall thickness.
Cyst morphology.
Presence of pneumothorax.
Associated nodules or ground-glass abnormalities.
Extrapulmonary findings.
Step 3: Investigate Confirmatory Features
Evaluate for:
Tuberous sclerosis complex.
Renal angiomyolipomas.
Lymphangioleiomyomas.
Chylous pleural effusion or ascites.
Step 4: Consider Serum VEGF-D
In patients with characteristic pulmonary cysts but no additional confirmatory features, serum VEGF-D testing can help establish the diagnosis.
A level of 800 pg/mL or higher supports definite LAM in the appropriate clinical setting.
A normal VEGF-D result does not exclude LAM.
Step 5: Histopathological Confirmation When Necessary
If the diagnosis remains uncertain and confirmation would influence clinical management, tissue sampling may be considered.
The least invasive appropriate diagnostic strategy should be preferred.
Step 6: Assess Disease Severity
Pulmonary function testing is important for evaluating:
FEV1.
Forced vital capacity (FVC).
Diffusing capacity for carbon monoxide (DLCO).
Lung volumes.
Oxygenation.
Serial pulmonary function measurements help identify disease progression and assess treatment response.
Figure 3. Proposed diagnostic pathway for suspected LAM, integrating HRCT, extrapulmonary findings, VEGF-D testing, pathology, and pulmonary function assessment.
8. Clinical Management: Pleurodesis and Sirolimus
8.1 Management of Spontaneous Pneumothorax
The initial priority in a patient presenting with a large pneumothorax is stabilization and appropriate management of the pleural complication.
Treatment depends on the size of the pneumothorax, clinical stability, respiratory compromise, and individual patient characteristics.
Pleural interventions may include drainage and pleurodesis.
An important consideration in LAM is the high recurrence rate of spontaneous pneumothorax.
The ATS/JRS guideline recommends offering ipsilateral pleurodesis after the initial pneumothorax rather than waiting for recurrence. The recommendation is conditional and emphasizes individualized decision-making (2).
In the present case, mechanical pleurodesis was performed. Nevertheless, the patient subsequently developed a contralateral pneumothorax.
This illustrates an important clinical distinction: treatment of one pleural space does not eliminate the risk of pneumothorax in the opposite lung.
8.2 Why Is Sirolimus Used?
Sirolimus, also known as rapamycin, is an mTOR inhibitor.
By suppressing abnormal mTOR signaling, sirolimus can reduce the proliferation of LAM cells and help stabilize pulmonary disease.
The treatment is particularly relevant in patients with abnormal or declining lung function.
The ATS/JRS guideline recommends sirolimus rather than observation for patients with LAM who have abnormal or declining lung function. The guideline defines abnormal lung function for this recommendation as FEV1 below 70% predicted (1).
8.3 Interpreting the Patient's Pulmonary Function Improvement
The patient initially demonstrated an FEV1 of 44% predicted.
After three months of sirolimus treatment, FEV1 improved to 67% predicted.
This improvement suggests a favorable physiological response during the reported treatment period.
However, the patient continued to experience fatigue and chest discomfort and remained unable to return to work.
Several factors may contribute to this difference between pulmonary function and functional recovery, including persistent respiratory symptoms, reduced physical conditioning, treatment-related adverse effects, and the broader impact of chronic disease.
The clinical response should therefore be assessed using more than FEV1 alone.
8.4 Monitoring During Sirolimus Therapy
Sirolimus requires careful clinical monitoring.
Potential adverse effects include:
Oral mucositis.
Hyperlipidemia.
Peripheral edema.
Acneiform skin reactions.
Proteinuria.
Cytopenias.
Increased susceptibility to infection.
Impaired wound healing.
The treatment plan should be individualized, with attention to pulmonary function, adverse effects, medication interactions, and patient-reported quality of life.
Sirolimus should not be interpreted as a cure for LAM. It is a disease-modifying treatment that can improve or stabilize important clinical outcomes in selected patients.
9. The Role of Radiology in Longitudinal Disease Monitoring
The contribution of radiology does not end when the diagnosis is established.
Imaging remains important throughout the clinical course.
9.1 Baseline Assessment
Initial HRCT provides information about:
Extent of cystic lung involvement.
Distribution and morphology of cysts.
Presence of pneumothorax.
Associated pleural abnormalities.
Extrapulmonary manifestations.
A well-documented baseline examination helps establish a reference for subsequent clinical evaluation.
9.2 Follow-Up Imaging
Follow-up imaging should be guided by clinical indications and the need to evaluate complications.
Chest radiography is particularly useful for assessing suspected recurrent pneumothorax.
CT may be appropriate when additional anatomical characterization is necessary.
Repeated CT examinations should be justified by clinical benefit, with attention to cumulative radiation exposure.
9.3 Imaging–Physiology Correlation
An important principle is that the extent of cystic abnormalities on CT and pulmonary function measurements provide complementary information.
HRCT demonstrates structural abnormalities, whereas pulmonary function testing measures physiological impairment.
Neither should be interpreted in isolation.
For example, a patient may have extensive cystic abnormalities but relatively preserved pulmonary function, while another may have substantial functional impairment.
Longitudinal assessment should integrate imaging, pulmonary function, symptoms, and treatment response.
10. Artificial Intelligence in the Diagnosis of Cystic Lung Disease
The diagnosis of LAM depends heavily on pattern recognition, anatomical distribution, and clinical context.
These characteristics create opportunities for artificial intelligence (AI) to support radiology workflows.
However, AI should be considered an adjunct to radiologist interpretation rather than an independent diagnostic authority.
10.1 Automated Pulmonary Cyst Detection
Deep-learning algorithms can potentially assist with:
Identification of pulmonary cysts.
Segmentation of cystic structures.
Quantification of cyst burden.
Measurement of cyst size and distribution.
Comparison of serial CT examinations.
A quantitative approach may help characterize disease burden more consistently than subjective visual assessment alone.
10.2 Three-Dimensional Lung Segmentation
Three-dimensional segmentation can potentially provide quantitative information about:
Total lung volume.
Cystic lung volume.
Cyst number.
Cyst size distribution.
Regional distribution of abnormalities.
Changes over time.
Such measurements could support longitudinal research and potentially improve the reproducibility of imaging assessments.
However, quantitative cyst burden should not be assumed to be a validated surrogate for clinical outcomes without appropriate clinical validation.
10.3 AI-Assisted Differential Diagnosis
A more advanced AI system could combine imaging features with clinical information to help distinguish LAM from other diffuse cystic lung diseases.
Potential inputs include:
Input | Potential AI application |
|---|---|
Patient demographics | Clinical context |
Smoking history | Differential diagnosis |
Cyst morphology | Pattern classification |
Cyst distribution | Disease differentiation |
Pulmonary nodules | Detection of associated abnormalities |
Ground-glass opacity | Identification of additional lung disease |
Renal lesions | Recognition of extrapulmonary clues |
Prior CT examinations | Longitudinal comparison |
The value of this approach lies in integrating multiple pieces of information rather than relying on a single imaging feature.
10.4 AI Detection of Pneumothorax
Pneumothorax is an established target for automated chest imaging analysis.
AI-based chest radiograph systems may assist with the detection and prioritization of pneumothorax.
In a patient with suspected LAM, this could potentially improve the identification of an acute pleural complication.
However, detecting pneumothorax and diagnosing its underlying cause are different tasks.
An AI system that identifies pleural air does not necessarily recognize the diffuse cystic lung disease responsible for the patient's increased susceptibility to pneumothorax.
This distinction is important when evaluating the clinical value of radiology AI.
10.5 Potential AI Workflow
A hospital-based AI workflow could be structured as follows:
This workflow illustrates how AI could be incorporated into an enterprise imaging environment.
10.6 AI Limitations and Diagnostic Safety
Several limitations must be considered before clinical implementation.
False-negative findings: Small or subtle cysts may be overlooked by an algorithm.
False-positive findings: Emphysematous spaces, vascular structures, and other low-attenuation abnormalities may be incorrectly classified as cysts.
Domain shift: An algorithm trained using one CT acquisition protocol may perform differently on images obtained with other scanners or reconstruction techniques.
Dataset bias: Rare diseases such as LAM may be inadequately represented in training datasets.
Automation bias: Radiologists may become overly dependent on algorithmic suggestions.
Limited clinical context: Image-only models may fail to incorporate smoking history, TSC status, renal findings, and laboratory information.
Consequently, human oversight remains essential.
The most meaningful future development is likely to involve multimodal AI systems that combine imaging, clinical information, pathology, and longitudinal pulmonary function data.
Such systems would need rigorous external validation before being used to guide clinical decisions.
11. Diagnostic Risk and Healthcare Workflow Implications
LAM provides an important example of how a seemingly straightforward emergency imaging finding can conceal a more complex underlying disease.
The immediate diagnosis of pneumothorax is important, but identifying the associated cystic lung disease can influence long-term management.
11.1 Potential Diagnostic Vulnerabilities
Several diagnostic problems may arise:
Anchoring bias: Focusing exclusively on the pneumothorax without evaluating the underlying pulmonary parenchyma.
Satisfaction of search: Stopping image interpretation after identifying the acute abnormality.
Incomplete image review: Failing to assess the full lung fields, including the costophrenic regions.
Pattern-recognition failure: Overlooking the characteristic distribution of pulmonary cysts.
Insufficient clinical correlation: Not considering the patient's sex, age, symptoms, and history of recurrent pneumothorax.
These are system-level vulnerabilities that can affect diagnostic performance, particularly in high-volume emergency radiology environments.
11.2 Clinical Consequences of Delayed Recognition
Failure to recognize the underlying disease may lead to:
Delayed evaluation for LAM.
Missed opportunities to identify extrapulmonary manifestations.
Delayed assessment of pulmonary function.
Inadequate long-term surveillance.
Delayed consideration of disease-modifying therapy.
The goal is not simply to identify the immediate emergency. It is to provide an interpretation that supports appropriate downstream clinical care.
11.3 Potential Economic Implications
Earlier recognition of LAM may improve the coordination of diagnostic evaluation and long-term management.
Potential healthcare-system benefits include more appropriate specialist referral, avoidance of unnecessary diagnostic procedures, and better coordination of follow-up.
However, the economic value of earlier diagnosis or AI implementation should not be assumed.
Any financial benefit would depend on actual clinical outcomes, resource utilization, integration costs, and the effectiveness of the implemented workflow.
12. Practical Radiology Pearls
1. Think of LAM when a woman presents with spontaneous pneumothorax and diffuse pulmonary cysts. This combination is an important diagnostic clue.
2. Evaluate cyst morphology and distribution. Multiple round, thin-walled cysts distributed throughout both lungs are characteristic of LAM.
3. Do not confuse pulmonary cysts with emphysema. True cysts have definable walls, whereas emphysematous spaces generally do not.
4. Look beyond the lungs. Renal angiomyolipomas, lymphangioleiomyomas, and chylous fluid collections can provide important diagnostic evidence.
5. Remember VEGF-D testing. A serum level of at least 800 pg/mL can support noninvasive diagnostic confirmation in an appropriate clinical setting.
6. Understand the pathological markers. The combination of smooth-muscle and melanocytic marker expression is characteristic of LAM cells.
7. Recognize the risk of recurrent pneumothorax. Pleurodesis after the initial event is recommended for consideration in patients with LAM.
8. Use pulmonary function testing for disease assessment. FEV1 and DLCO provide important information about functional impairment.
9. Recognize the role of mTOR inhibition. Sirolimus is an important disease-modifying treatment for patients with abnormal or declining lung function.
10. Integrate imaging with clinical and physiological findings. CT, pathology, pulmonary function, and clinical assessment provide complementary information.
13. Common Diagnostic Pitfalls
Diagnosing primary spontaneous pneumothorax without investigating the underlying lung parenchyma.
Misinterpreting diffuse cysts as emphysema.
Overlooking pulmonary Langerhans cell histiocytosis in patients with a smoking history.
Failing to consider Birt-Hogg-Dubé syndrome.
Assuming a normal VEGF-D level excludes LAM.
Performing invasive lung biopsy without first considering noninvasive diagnostic criteria.
Assuming pleurodesis eliminates the possibility of a contralateral pneumothorax.
Evaluating treatment response using FEV1 alone.
Assuming that improvement in pulmonary function guarantees complete symptomatic or occupational recovery.
Treating AI-generated findings as definitive diagnoses without radiologist verification.
14. Frequently Asked Questions
Q1. What is the most characteristic CT finding of lymphangioleiomyomatosis?
The most characteristic finding is multiple bilateral, diffuse, round, thin-walled pulmonary cysts involving both lungs. The cysts are generally distributed relatively uniformly and may involve the costophrenic regions.
Q2. Why does LAM cause spontaneous pneumothorax?
LAM produces progressive cystic destruction of the pulmonary parenchyma. Rupture of a subpleural cyst allows air to enter the pleural space, resulting in spontaneous pneumothorax.
Q3. Can LAM be diagnosed without lung biopsy?
Yes. A definite clinical diagnosis may be established when characteristic HRCT findings are accompanied by confirmatory features such as TSC, renal angiomyolipoma, lymphangioleiomyoma, chylous effusion, or elevated serum VEGF-D.
Q4. What is the significance of VEGF-D in LAM?
Serum VEGF-D is a useful noninvasive biomarker. A concentration of at least 800 pg/mL can support a definite diagnosis in patients with compatible clinical and HRCT findings. A normal result does not exclude the disease.
Q5. What is the role of sirolimus in LAM?
Sirolimus inhibits mTOR signaling, which is abnormally activated in LAM. It can stabilize or improve pulmonary function and is recommended for patients with abnormal or declining lung function.
Q6. Is LAM associated with tuberous sclerosis complex?
Yes. LAM may occur sporadically or in association with TSC. Evaluation for TSC is important because it can involve the kidneys, brain, skin, heart, and other organs.
Q7. What diseases should be considered in the differential diagnosis of diffuse pulmonary cysts?
Important considerations include pulmonary Langerhans cell histiocytosis, Birt-Hogg-Dubé syndrome, lymphocytic interstitial pneumonia, emphysema, and Pneumocystis jirovecii pneumonia.
Q8. Can AI help diagnose LAM?
AI may support cyst detection, segmentation, quantitative assessment, pneumothorax detection, and longitudinal comparison. However, distinguishing LAM from other cystic lung diseases requires clinical context and expert radiological interpretation.
15. Clinical Knowledge Check
Question 1. A 46-year-old woman presents with acute chest pain and dyspnea. Chest CT demonstrates a large pneumothorax and multiple diffuse, thin-walled pulmonary cysts. What is the most likely diagnosis?
A. Pulmonary emphysema
B. Pulmonary Langerhans cell histiocytosis
C. Lymphangioleiomyomatosis
D. Pneumocystis jirovecii pneumonia
E. Lymphocytic interstitial pneumonia
Question 2. Which immunohistochemical finding most strongly supports the diagnosis of LAM?
A. Isolated cytokeratin expression
B. Co-expression of smooth-muscle and melanocytic markers
C. Isolated CD20 expression
D. Isolated TTF-1 expression
E. Isolated S100 expression
Question 3. Which serum biomarker is particularly useful for noninvasive diagnostic confirmation of LAM?
A. C-reactive protein
B. Procalcitonin
C. Serum VEGF-D
D. Troponin
E. D-dimer
Question 4. What is the principal therapeutic mechanism of sirolimus in LAM?
A. Direct stimulation of alveolar regeneration
B. Inhibition of mTOR signaling
C. Suppression of pulmonary surfactant production
D. Enhancement of bronchial smooth-muscle contraction
E. Direct dissolution of pulmonary cysts
Question 5. Which imaging finding is most helpful in distinguishing typical LAM from pulmonary Langerhans cell histiocytosis?
A. Presence of pneumothorax alone
B. Diffuse, relatively uniform, round, thin-walled cysts
C. Isolated upper-lobe consolidation
D. Pleural effusion alone
E. Bilateral ground-glass opacity alone
Answers: 1-C, 2-B, 3-C, 4-B, 5-B.
16. Key Takeaways
Lymphangioleiomyomatosis is an important differential diagnosis in women presenting with spontaneous pneumothorax and diffuse pulmonary cystic abnormalities.
The major diagnostic and clinical principles are:
HRCT is central to recognizing the characteristic pulmonary cystic pattern.
The coexistence of pneumothorax and diffuse cysts should prompt investigation for LAM.
Extrapulmonary manifestations can provide important diagnostic evidence.
Serum VEGF-D can reduce the need for invasive lung biopsy in appropriately selected patients.
Histopathology and immunohistochemistry provide definitive confirmation when required.
Recurrent pneumothorax is an important complication.
Sirolimus targets abnormal mTOR signaling and can improve or stabilize pulmonary function.
Longitudinal assessment requires integration of imaging, pulmonary function, symptoms, and treatment response.
AI may improve image analysis and quantitative assessment, but clinical interpretation and human oversight remain essential.
The central radiological lesson is that the pneumothorax is the acute manifestation, whereas diffuse pulmonary cysts reveal the underlying disease. Recognizing both findings together is essential for accurate diagnosis and appropriate long-term clinical management.
17. Continue Learning
The following topics can strengthen the broader medical imaging knowledge network:
1. Differential Diagnosis of Diffuse Cystic Lung Disease on HRCT
[INTERNAL LINK PLACEHOLDER]
2. Pulmonary Langerhans Cell Histiocytosis: CT Findings and Diagnostic Approach
[INTERNAL LINK PLACEHOLDER]
3. Birt-Hogg-Dubé Syndrome: Pulmonary Cysts and Spontaneous Pneumothorax
[INTERNAL LINK PLACEHOLDER]
4. AI-Based Detection of Pneumothorax on Chest Radiographs
[INTERNAL LINK PLACEHOLDER]
5. High-Resolution CT in Interstitial Lung Disease: A Practical Radiology Guide
[INTERNAL LINK PLACEHOLDER]
References
1. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine. 2016;194(6):748–761. doi: 10.1164/rccm.201607-1384ST.
2. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2017;196(10):1337–1348. doi: 10.1164/rccm.201709-1965ST.
3. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. New England Journal of Medicine. 2011;364:1595–1606. doi: 10.1056/NEJMoa1100391.
4. Taveira-DaSilva AM, Moss J. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clinical Epidemiology. 2015;7:249–257. doi: 10.2147/CLEP.S50780.
5. Ryu JH, Moss J, Beck GJ, et al. The NHLBI LAM Registry: characteristics of 230 patients at enrollment. American Journal of Respiratory and Critical Care Medicine. 2006;173(1):105–111. doi: 10.1164/rccm.200409-1298OC.
6. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. American Journal of Respiratory and Critical Care Medicine. 2017;196(10):1337–1348.
7. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine. 2016;194(6):748–761.
Medical Disclaimer: This article is intended for medical education and professional discussion. Diagnosis and treatment decisions should be based on individual clinical findings, current evidence, and specialist evaluation.
Author: Dr. SangBock Lee
Editorial Team: ScholarGen MediAI
Copyright © 2026 ScholarGen Inc. All Rights Reserved.
Comments
Post a Comment